Search for Terms or Answers
Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is an autosomal-dominant autoinflammatory disease resulting from mutations of the TNF super family receptor 1A (TNFRSF1A) gene.
A study published in the British Medical Journal examines whether knee surgery or conservative medical management benefits those with degenerative meniscal tears. (Citation source http://buff.ly/2awVbKu)
Dr Jack Cush reviews this week's highlights from RheumNow.com.
Burmester and colleagues have published their review of the long-term outcomes and safety issues with the TNF inhibitor, adalimumab (ADA). The analysis included 15,132 patients exposed to adalimumab in global RA clinical trials.
Pregnancy complications of anti-phospholipid syndrome (APS) have included recurrent abortions, spontaneous fetal loss, preeclampsia, and premature birth. The etiopathogenesis of these events has been presumed to be placental thrombosis or infarction.
Rheumatology News has a novel online report about combined rheumatology-dermatology clinics. In the last several years, there have been a few of these in operation (Boston, Chicago, Rhode Island).
Vitamin D certainly plays a pivotal role in bone health and immune function.
Reuters reports that a study of 6629 Canadian women with osteoporosis taking bisphosphonates found that nearly one in five had a decrease in bone density while on medication. (Citation source: http://buff.ly/2afb7nj)
With the introduction of ASAS criteria for the diagnosis of axial and peripheral spondyloarthropathy, there has been a debate about whether patients with fibromyalgia (FM) could be mistaken for a spondyloarthropathy, or vice versa.
SAPHO is an acronym that describes a constellation of findings (synovitis, acne, pustulosis, hyperostosis, and osteitis) that defines this rare syndrome.
In the last 6 months, the FDA Arthritis Advisory Committee has recommended three biosimilars (CT-P13, GP-2015, ABP-501) for approval, with one achieving FDA approval Inflectra/CT-P13) and the other two pending a probable approval in the months to come.
Porter and colleagues have reported that both rituximab (RTX) and tumour necrosis factor inhibitors (TNFi) are equally and highly effective in early, active, biologic-naive rheumatoid arthritis patients.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
